Our GLP1 HVP business also performed very well, accelerating nicely in the quarter, growing well into the 30s organically. HPP GLP1s represented just under 12% of total revenues in the quarter. We continue to remain optimistic about the long-term growth prospects of the GLP1 category, driven by the continued adoption of existing products, the potential for for expansion into new therapeutic categories, ? the development of next generation molecules, and increasing access in certain markets as generics are launched. ? Now, looking at other product categories in the proprietary segment, HVP delivery device revenues were $99 million in the quarter. This was flat on a reported basis and up 26% organically after excluding currency and the impact of the SmartDOS 3.5 domestic ? term. Both Crystal Zenith and admin systems contributed to growth in the quarter. Of note, in Q three we generated twelve million dollars in Smart Dose 3.5 revenue, which wasn't included in our Q3 guidance. This compared to $30 million in Q3 of last year. Both figures, along with FX, have been excluded to calculate our organic growth in the quarter. As we've previously mentioned, Smart Dose 3.5 product revenues were $55 million in the second half of last ? year, $30 million in Q3, and another $25 million in Q4. Those figures, along with the $12 million in Q3 of this year, are excluded from our organic growth calculations. And now that we've closed the transaction and do not expect any additional Smart Dose 3.5 product revenues going forward, I want to provide the Smart Dose 3.5 revenue details for this year to help you with your modeling for next year. SmartDose 3.5 revenues were $100 million this ? year, $46 million in Q1, $42 million in Q2, ? and $12 million this quarter, as I just mentioned. Consistent with this year, we will exclude those revenues from next year's organic growth calculations, but this will result in a roughly 290 basis point headwind to reported growth next ? year. And lastly, in standard products, revenues of $163 million were up up 3% on an organic basis. ? Now let's move to our West Bandage segment. West Bandage delivered $146 million in revenue, declining 6.6% on an organic basis, slightly better than expected, as we were able to fully recover the revenue deferred by the cyber incident in Q3 versus Q3 and Q4. ? As Michelle stated earlier, the year-on-year decline was expected as incremental sales from new programs were more than offset by the decline associated with the roll off of a CGM program starting this quarter. ? And looking by geography, we delivered solid growth across each of our three geographies. Our smallest geography, Asia Pacific, representing 11% of our total company revenues, grew 42%, led by India and China. America's grew 12%, while AMEA grew 6%, as good growth in proprietary was partially offset by the CGM program roll off in West Vantage. ? Now let's take a closer look at the rest of the PL. Total company growth margin was 39.7% in the quarter, up 310 basis points year over year. ? The year on year increase was primarily driven by better than expected proprietary product sales and the associated positive mix shift to HBP components as well as price contribution. ? We have been able to offset inflationary pressures on our cost base through good plant performance and some cost recovery via pass-through. ? While West Bandage gross margin was down year-on-year, it improved sequentially. Adjusted operating margins of 25.3% were up 420 basis points compared to the prior year, driven primarily by the gross margin expansion and leveraging our SGNA cost base. We also benefited from improved below-the-line performance in the quarter, as our adjusted tax rate was a better than expected 17%, and we had 70.8 million diluted shares outstanding. Adding it all up, Q3 adjusted earnings per share were $2.66, up 36% versus last year and 47 cents above the midpoint of guidance we gave on the last earnings call. Before moving into our updated guidance, I did want to highlight a few additional financial metrics. For the first nine months of this year, we delivered free cash flow, that's operating cash flow left CapEx, of $278 million. This is roughly a 5% decrease compared to the same period in 2025, due primarily to increases in customers' accounts receivable, as well as increased inventory levels to support our operations, partially offset by lower capital spending. This is an improvement from Q2's results, and we expect continued improvement in Q4. For the first nine months of 2026, capital expenditures were $125 million, lower than initially planned, and we now expect full-year CapEx to be between $215 ? to $220 million for the year. This is still within our 6-8% of revenue corridor, albeit at the low ? end. We continue to be focused on investing for growth ? and are kicking off a new wave of meaningful capital investments to expand our HVP finishing capacity both in Europe and the US. That said, we expect to remain in that six to eight percent of revenue range for CapEx spending in the future. The success of our global operations this year has put us onto more solid footing as we have been adding and training new shifts and optimizing our global network and increasing capacity. Our Q3 outperformance is a great example of the success of our teamwork. We are well positioned to finish the year strong, and the new HVP finishing capacity expansions will further support growth in the coming years. Additionally, from a balance sheet perspective, earlier this week, ? we upsized our revolver to $750 million and renewed for another five years, providing balance sheet flexibility. We also continue to return cash to shareholders via our dividends and share repurchase plans. Year to date, ? we paid out $47 million in dividends and just announced our 34th consecutive year of dividend increases with an 18% increase in the dividend in the quarter. And for this first nine months of this year, we have repurchased just over 2.4 million shares for $685 million. Our cash flow and strong balance sheet continue to position us well as we deploy capital for growth and deliver value to our shareholders. In summary, we had a strong third quarter that exceeded our expectations on the top and bottom lines, and are pleased that our solid business momentum continues. ? And now let me turn to our updated guidance. Given the strong third quarter, we now anticipate full year revenue to be in the range of $3.41 to $3.42 billion. Up from a prior range of $3.345 billion to $3.38 billion. This revised guidance assumes full year 2026 organic sales growth of 11.3% to 11.6%, up from a prior range of 10 to 11%. FX is expected to have a full year benefit of 120 basis points, ? while the SMARTDOS 3.5 divestiture negatively impacts reported growth by 160 basis points. This translates to Q4 revenues of $820 to $830 million, an improvement from our Q4 implied guidance last quarter, and represents 6 to 7% organic revenue growth. Consistent with the first nine months of the year, we expect Q4 will be driven by double digit growth in HPB components. This prudent guide absorbs incremental negative FX as the dollar has strengthened in the past month, and the ? West Vantage Q3 pulled forward. Full year 2026 adjusted EPS is expected to be in the range of $9.38 to $9.48, up from a prior range of $8.85 to $9.05. This now represents growth of 29 to 30% year over year. We expect full year operating margins to expand almost 300 basis points, driven by gross margin expansion and SGNA leverage. This is above our long-term growth construct of 100 basis points per year improvement, as we have benefited this year from stronger than expected revenue growth, portfolio optimization, mix, and SGA leverage. ? And to help you with your models below the line for the full year, we're projecting $5 million of net interest income, a tax rate for the full year slightly lower than 18%, roughly $18 million in affiliate profits, and $1.4 million diluted shares outstanding for the ? year. In summary, we're very pleased with how our business is performing. We're well positioned to finish the year strong, and we look forward to introducing 2027 guidance on our Q4 earnings call in February. ? Now I'd like to turn the call back to Michelle for closing comments. Michelle.
Passages & reports (66) 9:05 Our GLP1 HVP business also performed very well, accelerating nicely in the quarter, growin… Report 9:25 driven by the continued adoption of existing products, the potential for for expansion int… Report 9:33 the Report 9:33 development of next generation molecules, and increasing access in certain markets as gene… Report 9:40 Now, Report 9:41 looking at other product categories in the proprietary segment, HVP delivery device revenu… Report 9:58 term. Report 9:58 Both Crystal Zenith and admin systems contributed to growth in the quarter. Of note, in Q … Report 10:18 have been excluded to calculate our organic growth in the quarter. As we've previously men… Report 10:30 year, Report 10:31 $30 million in Q3, and another $25 million in Q4. Those figures, along with the $12 millio… Report 10:50 going forward, I want to provide the Smart Dose 3.5 revenue details for this year to help … Report 11:03 year, Report 11:03 $46 million in Q1, $42 million in Q2, Report 11:08 and Report 11:08 $12 million this quarter, as I just mentioned. Consistent with this year, we will exclude … Report 11:23 year. Report 11:24 And lastly, in standard products, revenues of $163 million were up up 3% on an organic bas… Report 11:32 Now Report 11:33 let's move to our West Bandage segment. West Bandage delivered $146 million in revenue, de… Report 11:52 As Report 11:52 Michelle stated earlier, the year-on-year decline was expected as incremental sales from n… Report 12:05 And Report 12:05 looking by geography, we delivered solid growth across each of our three geographies. Our … Report 12:25 proprietary was partially offset by the CGM program roll off in West Vantage. Report 12:30 Now Report 12:31 let's take a closer look at the rest of the PL. Total company growth margin was 39.7% in t… Report 12:41 The Report 12:41 year on year increase was primarily driven by better than expected proprietary product sal… Report 12:53 We Report 12:54 have been able to offset inflationary pressures on our cost base through good plant perfor… Report 13:01 While Report 13:02 West Bandage gross margin was down year-on-year, it improved sequentially. Adjusted operat… Report 13:22 from improved below-the-line performance in the quarter, as our adjusted tax rate was a be… Report 13:42 and 47 cents above the midpoint of guidance we gave on the last earnings call. Before movi… Report 14:01 million. This is roughly a 5% decrease compared to the same period in 2025, due primarily … Report 14:21 continued improvement in Q4. For the first nine months of 2026, capital expenditures were … Report 14:35 to Report 14:36 $220 million for the year. This is still within our 6-8% of revenue corridor, albeit at th… Report 14:43 end. Report 14:43 We continue to be focused on investing for growth Report 14:46 and Report 14:46 are kicking off a new wave of meaningful capital investments to expand our HVP finishing c… Report 15:06 more solid footing as we have been adding and training new shifts and optimizing our globa… Report 15:26 coming years. Additionally, from a balance sheet perspective, earlier this week, Report 15:31 we Report 15:32 upsized our revolver to $750 million and renewed for another five years, providing balance… Report 15:47 we Report 15:48 paid out $47 million in dividends and just announced our 34th consecutive year of dividend… Report 16:08 cash flow and strong balance sheet continue to position us well as we deploy capital for g… Report 16:28 And Report 16:28 now let me turn to our updated guidance. Given the strong third quarter, we now anticipate… Report 16:48 revised guidance assumes full year 2026 organic sales growth of 11.3% to 11.6%, up from a … Report 17:04 while Report 17:05 the SMARTDOS 3.5 divestiture negatively impacts reported growth by 160 basis points. This … Report 17:24 revenue growth. Consistent with the first nine months of the year, we expect Q4 will be dr… Report 17:42 West Report 17:42 Vantage Q3 pulled forward. Full year 2026 adjusted EPS is expected to be in the range of $… Report 18:02 year over year. We expect full year operating margins to expand almost 300 basis points, d… Report 18:23 portfolio optimization, mix, and SGA leverage. Report 18:28 And Report 18:28 to help you with your models below the line for the full year, we're projecting $5 million… Report 18:45 year. Report 18:46 In summary, we're very pleased with how our business is performing. We're well positioned … Report 19:00 Now Report 19:00 I'd like to turn the call back to Michelle for closing comments. Michelle. Report